Gross-Goupil M - Search Results

1

Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study.

de Vries-Brilland M, Gross-Goupil M, Seegers V, Boughalem E, Beuselinck B, Thibault C, Chevreau C, Ladoire S, Barthélémy P, Negrier S, Borchiellini D, Huillard O, Geoffrois L, Gravis G, Saldana C, Thiery-Vuillemin A, Escudier B, Ravaud A, Albiges L. de Vries-Brilland M, et al. Eur J Cancer. 2020 Sep;136:76-83. doi: 10.1016/j.ejca.2020.02.019. Epub 2020 Jul 9. Eur J Cancer. 2020. PMID: 32653774

2

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.

Gross-Goupil M, Lokiec F, Lopez G, Tigaud JM, Hasbini A, Romain D, Misset JL, Goldwasser F. Gross-Goupil M, et al. Eur J Cancer. 2002 Sep;38(14):1888-98. doi: 10.1016/s0959-8049(02)00232-0. Eur J Cancer. 2002. PMID: 12204671 Clinical Trial.

3

The postchemotherapy PSA surge syndrome.

Thuret R, Massard C, Gross-Goupil M, Escudier B, Di Palma M, Bossi A, de Crevoisier R, Chauchereau A, Fizazi K. Thuret R, et al. Ann Oncol. 2008 Jul;19(7):1308-1311. doi: 10.1093/annonc/mdn062. Epub 2008 Mar 19. Ann Oncol. 2008. PMID: 18356135 Free article.

4

[Revolution in treatment of renal carcinoma: molecular rational and clinical approach].

Escudier B, Gross-Goupil M. Escudier B, et al. Med Sci (Paris). 2008 Aug-Sep;24(8-9):697-9. doi: 10.1051/medsci/20082489697. Med Sci (Paris). 2008. PMID: 18789213 Free article. French. No abstract available.

5

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

6

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

7

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Michels J, et al. Invest New Drugs. 2010 Oct;28(5):690-3. doi: 10.1007/s10637-009-9275-z. Epub 2009 Jun 24. Invest New Drugs. 2010. PMID: 19547920

8

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.

Massard C, Fizazi K, Gross-Goupil M, Escudier B. Massard C, et al. Invest New Drugs. 2010 Dec;28(6):879-81. doi: 10.1007/s10637-009-9295-8. Epub 2009 Aug 1. Invest New Drugs. 2010. PMID: 19649567 No abstract available.

9

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Massard C, et al. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22. Ann Oncol. 2010. PMID: 19850637 Free article. Clinical Trial.

10

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters